12:00 AM
 | 
Feb 11, 2013
 |  BC Week In Review  |  Company News  |  Deals

Aduro Biotech, BioSante deal

Aduro said it acquired all assets related to BioSante's GVAX cancer vaccines, including IP and cell lines, for $1 million up front and undisclosed milestones plus royalties. Aduro, which already has rights to GVAX vaccines to treat pancreatic and prostate cancer, will gain...

Read the full 192 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >